Remove 2020 Remove Chemotherapy Remove Immunization
article thumbnail

The top 5 pharma M&A deals of 2020

pharmaphorum

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% of total M&A deal values. Here we take a look at the biggest mergers and acquisitions of 2020 and what they might mean for the companies involved.

article thumbnail

The end-of-life care conundrum

pharmaphorum

Over recent years, there has been a growing consensus that using chemotherapy and aggressive treatments towards the end-of-life should be avoided, where possible, due to the lower quality of life reported. Once no cure can be found for a patient’s condition, decisions must be made about what is the most suitable path forwards.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

VBL craters as ovarian cancer gene therapy fails phase 3 test

pharmaphorum

The study compared VB-111 plus paclitaxel chemotherapy to paclitaxel given on its own, but showed no significant difference between the two groups, with PFS and OS in both coming in at just over five months and 13 months, respectively.

article thumbnail

Transforming oncology with antibody therapeutics

European Pharmaceutical Review

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. 2020; 19(10): 2044–56.

article thumbnail

Sugemalimab plus chemo boosts lung cancer survival, trial reveals

pharmaphorum

EQRx’s GEMSTONE-302 study evaluated the efficacy and safety of the investigational anti-PD-L1 antibody, sugemalimab, in combination with chemotherapy as a first-line treatment for patients with stage four non-small cell lung cancer (NSCLC), versus using chemotherapy alone. In 2020, an estimated 2.2

article thumbnail

Who should not take probiotics?

The Checkup by Singlecare

A healthy gut biome is crucial to your immune system and regulates proper digestion, bowel movements, and other bodily functions. People with compromised immune systems. For those with a weakened immune system, allergies, or illness, it’s crucial to consult with your healthcare provider. People with a severe illness.

article thumbnail

Governments and pharma relationships and implications for antimicrobial resistance

Pharmaceutical Technology

Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. AMR occurs when disease-causing bacteria become resistant or immune to the antibiotics used to treat them.